Novel Vaccine Approaches for Emerging RNA Viruses
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: closed (31 May 2021) | Viewed by 6423
Special Issue Editor
Special Issue Information
Dear Colleagues,
Emerging RNA viruses continue to pose a unique threat to global human health. Since the turn of the century, we have witnessed new and on-going global pandemics due to influenza viruses, chikungyna virus, West Nile virus, Zika virus, dengue virus, SARS coronaviruses, and many more. With continued population growth and international connections, we need to focus on development of unique and novel vaccine approaches to address this ongoing global health problem. This special issue seeks manuscripts that evaluate new approaches to develop vaccine technology in the field of emerging RNA viruses. These approaches can include basic proof-of-concept approaches for vaccine development, novel adjuvant approaches, immunology of vaccine approaches, and translational efforts to evaluate immunogenicity and efficacy of a vaccine approach for emerging RNA viruses. We are particulary interested in manuscripts that evaluate novel platforms for rapid vaccine development. A continued and persistent effort to develop novel vaccine candidates and approaches for a variety of RNA viruses will provide an important pipeline of data as new RNA viruses emerge and threaten global human health in the future.
Dr. David Beckham
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- RNA virus
- vaccines
- emerging viruses
- immunogenicity
